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Education and debate
Evidence based policy: proceed with care
Nick Black
The emergence of evidence based medicine in the
early 1990s led to some clinicians challenging manag›
ers and policymakers to be equally evidence based in
their policymaking. This demand was shared by some
health policy analysts: “At a time when ministers are
arguing that medicine should be evidence›based, is it
not reasonable to suggest that this should also apply to
health policy? If doctors are expected to base their
decisions on the findings of research surely politicians
should do the same . . . the case for evidence›based
policymaking is difficult to refute.”1
The need to be seen to be making evidence based
decisions has permeated all areas of British public
policy. The government has proclaimed the need for
evidence based policing, and the 1998 strategic
defence review introduced evidence based defence.2 In
the health sector, the concept of evidence based policy
has gained ground, and a journal has been launched
devoted to this challenge (Journal of Evidence Based
Health Policy and Management).
Despite some groups using evidence based policy
as a fig leaf, it seems difficult to argue with the idea that
scientific research should drive policy. However, before
accepting the argument we need to understand the
implied model of policymaking.
What is the implied model of
policymaking?
In essence, protagonists assume that the relation
between research evidence and policy is linear3; a
problem is defined and research provides policy
options. Research is used to fill an identified gap in
knowledge. This is consistent with both a positivist
model of science and professional dominance, in
which the views and priorities of healthcare
professionals (and doctors in particular) dominate
healthcare policies. It assumes research evidence can
and should influence health policy. Lomas has
suggested that the model is viewed as “a retail store in
which researchers are busy filling shelves of a
shop›front with a comprehensive set of all possible
relevant studies that a decision›maker might some day
drop by to purchase.”4
Discussion of the theory underlying evidence
based policy might safely be consigned to an intellec›
tual dustbin if it were not for the practical
consequences. If we accept a linear relation, then the
value of research will inevitably be judged in terms of
its impact on policy. Few would argue with “the need
to show that public investment in research results in
benefits for patients,”5 but politicians and managers
take it a stage further, requiring “a substantial return
from investment in health services research.”6 This
implies that at least some aspects of the impact of
research can and should be quantifiable, even in
monetary terms.
The consequences of failure to show benefit are
fairly clear. So, how successful have researchers been at
facilitating evidence based policy?
Is healthcare policy evidence based?
Several studies have been conducted on the relation
between research and policymaking over the past five
years. A useful distinction has been made between
practice policies (use of resources by practitioners),
service policies (resource allocation, pattern of
services), and governance policies (organisational and
financial structures).7
Practice policies
The relation between research evidence and clinical
practice has been thoroughly examined by practition›
ers of evidence based medicine. Clinical effectiveness
should clearly play a large part in determining practice
policy. Concern has focused on the delays observed in
implementation of research findings.8
Summary points
Evidence based policy is being encouraged in all
areas of public service, including health care
Research currently has little direct influence on
health services policy or governance policies
The implicit assumption of a linear relation
between research evidence and policy needs to be
replaced with a more interactive model
Researchers need a better understanding of the
policy process, funding bodies must change their
conception of how research influences policy, and
policy makers should become more involved in
the conceptualisation and conduct of research
Until then, researchers should be cautious about
uncritically accepting the notion of evidence
based policy
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The linear, rationalist model holds up quite well for
practice policy, although it shows signs of strain in two
ways. Firstly, policymakers differ in their interpretation
of the evidence. For example, guidelines on cholesterol
testing vary considerably both between and within
countries.9 Such differences reflect variations in context
(values) and in the background of the policymakers.
Generally, the more that clinicians are involved, the less
the policy reflects the evidence.
Secondly, there is a lack of generalisability once we
move away from drugs to manual interventions. For
example, difficulty in devising practice policies in
surgery arises because decisions depend on the features
of the particular patient (obesity, anatomy, quality of
tissue), the particular surgeon, and various external
factors (equipment available, competence of assistants).10
Service policies
Although research has made some important contri›
butions to support service developments, the relation
between research evidence and service policies is gen›
erally weak. The box lists the six main reasons, which
are discussed below.
Firstly, some policymakers have goals other than
maximising clinical effectiveness. The goal may, for
example, be social or financial. The UK government’s
decision to aim the safe sex campaign in the 1980s at
the entire population, rather than those at high risk,
owed nothing to research but to avoiding a possible
backlash against gay men and black people.11 And the
introduction of the prenatal triple test for detecting
Down’s syndrome helped providers fulfil their
contract with local purchasers.12 Even terms and con›
ditions of employment of staff can justify a policy.
Decisions regarding health promotion in primary care
in the early 1990s were influenced by negotiations on
the general practitioner contract between the profes›
sion and the department of health.13 Policy may also
be shaped by electoral considerations. For example,
the Changing Childbirth policy in the 1990s was
politically led with no secure scientific base.14 Local
policymakers are therefore under a myriad of often
competing pressures, of which scientific evidence is
but one.
Secondly, research evidence may be dismissed as
irrelevant if it comes from a different sector or
specialty. For example, general practitioners have been
reluctant to extrapolate the results of randomised
trials on the use of anticoagulants to primary care
because the studies were carried out in hospitals.14
Evidence may also be dismissed in areas where
practice often depends on tacit knowledge, such as
surgery. Perceived lack of applicability can also lead to
dismissal—because research on the effectiveness of
interferon alfa for hepatitis C was confined to patients
with no other serious health problems, the evidence
has been seen as irrelevant for a population with high
comorbidity.15
Thirdly, there may be a lack of consensus about the
research evidence because of its complexity, scientific
controversy (incomplete or inconsistent evidence), or
different interpretations. Policy on preventing heart
disease in primary care has suffered from widely differ›
ing interpretations of the results of the two major ran›
domised trials.13
Fourthly, policymakers may value other types of
evidence such as personal experience, local infor›
mation on services, eminent colleagues’ opinions, and
medicolegal reports. Fifthly, the social environment
may not be conducive to policy change. Attempts at
introducing evidence based needs assessment have
been hampered by frequent organisational changes
lowering staff morale.16 And finally, the quality of the
“knowledge purveyors” may be inadequate. These are
the people who carry the research evidence into the
policymaking forums. In central government, civil
servants usually have this crucial role. In the United
Kingdom, a high turnover of such staff, lack of experi›
ence in a particular field, and high workload militate
against good quality advice.17
Governance policies
The direct influence of research on governance
policies has been negligible. This is illustrated by the
reorganisations of the NHS in 1974 and 1989. In both
cases research evidence was ignored but for different
reasons.11 In 1974, there was a consensus—unification
of services was necessary, as was coterminosity with
local government. Therefore, no research evidence was
needed. Instead working parties were set up in which
decisions were based on experiential evidence. In con›
trast, in 1989 policy was largely influenced by ideology
and electoral considerations. Ambiguous research evi›
dence (such as on the merits of competition in the
United States) was used selectively.
A second example is the policy of introducing
managed care.18 Evidence from the United States has
been used both by proponents and opponents. Oppo›
nents noted that of 81 published observations of
outcomes, 68 showed no significant advantage for
managed care. Meanwhile, proponents pointed out
that in the other 13 observations, managed care
organisations achieved lower use of services and of
expensive tests and procedures (where alternatives
existed) without compromising quality of care. In
effect, research evidence has had little effect on the
policy to introduce managed care.
Clearly, research has only a limited role because
governance policies are driven by ideology, value
judgments, financial stringency, economic theory,
political expediency, and intellectual fashion.19 It
would be naive and unrealistic to expect research to
Reasons why research evidence has little
influence on service policies
Policymakers have goals other than clinical
effectiveness (social, financial, strategic development
of service, terms and conditions of employees,
electoral)
Research evidence dismissed as irrelevant (from
different sector or specialty, practice depends on tacit
knowledge, not applicable locally)
Lack of consensus about research evidence
(complexity of evidence, scientific controversy, different
interpretations)
Other types of competing evidence (personal
experience, local information, eminent colleagues’
opinions, medicolegal reports)
Social environment not conducive to policy change
Poor quality of knowledge purveyors
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provide evidence to clinch arguments about govern›
ance policies.
Lessons
Several conclusions can be drawn from the above dis›
cussion of practice, service, and governance policies.
Firstly, research has little direct influence on service
and governance policy if we adopt those criteria set
and accepted by researchers. Secondly, the relation
between research and policy depends on the arena
and, thus, the policymakers. Research evidence is more
influential in central policy than local policy, where
policymaking is marked by negotiation and uncer›
tainty. Thirdly, the use of research depends on the
degree of consensus on the policy goal. It is used if it
supports the consensus and is used selectively if there
is a lack of consensus. Fourthly, many researchers are
politically naive. They have a poor understanding of
how policy is made and have unrealistic expectations
about what research can achieve. And, fifthly, policy›
making is not an event but is “ethereal, diffuse, haphaz›
ard and somewhat volatile.”4 The consequences of fail›
ing to understand this are clear: “So long as
researchers presume that research findings must be
brought to bear upon a single event, a discrete act of
decision making, they will be missing those circum›
stances and processes where, in fact, research can be
useful.”20 In other words, we need a better model to
underpin the relation.
What other models of policymaking exist?
An alternative view was proposed by Weiss in the
1970s, the enlightenment model.21 In this model,
research provides a new way of conceptualising the
world, mapping the decision making terrain, and chal›
lenging conventional assumptions. Research is seen as
one of several knowledge sources and cannot speak for
itself in policy terms. Evidence based policy is not sim›
ply an extension of evidence based medicine: it is
qualitatively different. Research is considered less as
problem solving than as a process of argument or
debate to create concern and set the agenda. During
the 1980s and 1990s this view was extended to a more
interactive model based on a close dialogue between
researchers and policymakers in which knowledge is
considered to be inherently contestable.22
The implication of accepting this model is that
policymakers have to get something out of research if
they are to use it. It is necessary, therefore, to consider
which arguments are likely to be useful or gratifying to
which policymakers. Researchers have to accept that
their work may be ignored because policymakers have
to take the full complexity of any situation into
account. They need to recognise that the other
legitimate influences on policy (social, electoral, ethical,
cultural, and economic) must be accommodated and
that research is most likely to influence policymakers
through an extended process of communication.
The challenge that this represents for researchers
is considerable. We can see why if we look at the
factors that influence policy decisions (box).4
Researchers have tended to focus on enhancing the
strength of the information available, with disappoint›
ing results. For research to have an impact it is neces›
sary to target the values of the policymakers. As
ideologies and interests are almost impossible to
change, researchers’ main target is to challenge and
change beliefs. This is difficult because they are
competing with other sources of persuasion and have
to counteract pressure to reject research evidence if it
is incompatible with policymakers’ interests and
ideologies. In addition, beliefs change only slowly and
under repeated exposure.
How can research be more influential?
Change in researchers’ attitudes
Researchers need to acquire a more sophisticated
understanding of the policy process. They need to
understand that there are many sorts of evidence, that
sensible decisions may not reflect scientific rationality,
and that context is all important, particularly with poli›
cies related to services and governance. They must also
resist simplistic payback models, recognise the
difficulty of identifying and quantifying the contribu›
tion of research, and be prepared to defend the
unmeasurable. One of the most useful roles for
research is to make people review their beliefs and
legitimise unorthodox views.
Change in funders’ understanding
Those who fund and commission research need to
review their conception of how research influences
policy. Interesting new approaches are being adopted
that are consistent with a more complex model—for
example, the use of modelling to predict whether
research is likely to have any impact23; iterative tender›
ing to improve the dialogue between researcher and
policymaker24; encouragement of policymakers to
invest directly in research25; and shifting the responsi›
bility for commissioning from scientists to the end
users of the research, as is happening with the new
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Lomas’s framework for understanding
policymaking4
Institutional structure—its design, who is involved,
rules of conduct
Values—based on beliefs, ideologies, interests
Information—research, anecdote, experience,
propaganda
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NHS service delivery and organisation research and
development programme. Funders must also recog›
nise the limited value of single studies. Generally, the
results of a single study are not worth disseminating.
Syntheses of the results of studies are the appropriate
product of research endeavour.
Change in the way research is conducted
Policymakers need to be more involved in the concep›
tualisation and conduct of research. Researchers need
greater access to information on the priorities of poli›
cymakers, who in turn need to organise and commu›
nicate their needs better.26 A closer relation between
the two groups needs to be sustained during the
research and beyond if the work is to have any impact.
A “policy community” needs to be created with the
appropriate people—this might include civil servants
to purvey knowledge into policymaking forums, jour›
nalists to engender wider interest, and practitioners
who will translate the new knowledge into practice.27
And all of this activity needs to be cognisant of timing.
Windows of opportunity to make major change open
up only rarely and briefly, when policymakers’ values
happen to coincide with the implications of research.
It’s like the offside trap in football: go too soon, you’re
caught offside and nothing ensues; go too late and
your progress will be opposed.28
I thank Maureen Dalziel, Renee Danziger, Rudolf Klein, Steven
Lewis, Jonathan Lomas, and Nick Mays for enlightenment. This
paper is based on the Cochrane lecture given on 6 September
2000 at the Society for Social Medicine Annual Scientific Meet›
ing, University of East Anglia.
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Commentary: research must be taken seriously
Anna Donald
Black rightly identifies the limits of evidence based
practice—mainly, that it does not always work.
Non›scientific factors, such as vested interests, often
override the most convincing research, and decision
makers cannot always agree on its merits.
These problems certainly exist. Research findings
are seldom black and white; nor are practitioners per›
fectly trained to interpret them. Policy decisions are
almost always made in the context of money, power,
and precedent, and these factors will therefore usually
affect the decision. The important question, though, is
not that these factors exist, but the extent to which
they hold sway, especially in the face of good research.
And beyond that lies a question of what evidence
based practice and evidence based medicine are all
about.
I do not recognise Black’s portrayal of evidence
based medicine as an overrationalised, mechanistic
process to replace the realpolitik surrounding major
policy decisions. As he intimates, the idea that research
could sweep away the time consuming but necessary
process of weighing up policies from all angles is naive.
I can understand that researchers, whose blood, sweat,
and tears pour into their work for decades, might have
liked to do away with civil servants and implement
their research directly into policy, but this was never a
possibility.
Rather, in the United Kingdom, evidence based
medicine was introduced in public health to improve
not only policy outcomes but also the accountability
mechanisms by which decision were made. At that
time, the NHS had undergone substantial change
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based largely on ideological opinion. People were fed
up with the extent to which politicians’ whims could
change their lives—not obviously for the better.
Evidence based medicine was propelled on a wave of
enthusiasm for something that could reduce the nega›
tive effects of uninformed authority, just as scientific
rationalism was eagerly promoted by people longing
to be free of the blind authority of the Church. In this
domain—shifting the politics of decision making by
mandating better accountability— it can be argued that
evidence based medicine and practice was successful
beyond anyone’s wildest dreams.
Change in perception
Black’s early examples illustrate how before the
mid›1990s, and before the term evidence based began
to gain common parlance and popularity in Britain,
the relation between policy and research was dismal.
Since that time there has been a sea change in people’s
expectation that research should be taken seriously.
There are so many examples: screening policies, the
recent House of Lords’ decision on emergency contra›
ception, the demise of general practitioner fundhold›
ing,1 the move towards more aggressive treatment for
ischaemic heart disease. Perhaps more important,
however, is that the change in people’s expectations
has been so widespread. Individual doctors, nurses,
local managers, health visitors, and the public now care
enough about research to be palpably frustrated when
it cannot be found or implemented.
That is not to say that policy decisions perfectly
reflect research findings, nor that research is easy to use
in policy. But just because taking research seriously
enough to create infrastructure and rules about it is
difficult and imperfect does not mean that it should be
viewed with caution. As a form of governance, democ›
racy is also difficult and imperfect, and terrible things
happen that shouldn’t—corruption, war, poverty, and
crime. Yet that does not mean that we yearn to return
to less questioning and more precarious forms of gov›
ernance such as oligarchies and dictatorships, however
benign. Taking research seriously—being evidence
based—is a discipline requiring decades of work to
ensure its support through good times and bad. I do
not agree than now is the time to put on the brakes.
Competing interests: AD works with many governmental, com›
mercial, and charitable organisations to implement evidence.
1 Robinson R, Le Grand J. Evaluating the NHS reforms. London: King’s
Fund, 1993.
Patient led conferences: an education for doctors
Scientific conferences are an excellent way of keeping
up to date with the latest developments in your
subject. They are also a useful means of recharging
your batteries away from the relentless timetable of
clinical service, and an opportunity to share
experiences with colleagues in the same specialty.
Having become interested in pituitary disease, I
decided to go to the Pituitary Foundation’s annual
conference. This foundation is a patient led
organisation that provides support, advice, and
education for patients with the whole spectrum of
pituitary pathology.
In contrast to previous conferences I have attended,
where familiar faces of past and present colleagues
abound, I found that I was one of only a few doctors
present (apart from the few eminent professors who
had been invited to run the Patient Workshops). It was
with some trepidation that I joined the acromegaly
workshop. Having got over the initial shock of seeing
60 pairs of spade›like hands being raised
simultaneously when their owners volunteered their
personal concerns, I started to find out what pituitary
patients were worried about. They were interested in
new treatments for the disease, how to find the most
experienced surgeon, whether they were allowed a
choice in who did their operation, and whether the
replacement hormones they were taking were for life
or whether they would be retested at some stage.
I then proceeded to the psychology workshop,
where I found that many patients had become severely
anxious and depressed while taking dopamine agonists
but were told that it was essential to continue these
drugs to normalise their prolactin levels. I also found
that patients with pituitary disease suffered from severe
migraines, a problem that I think has sufficient clinical
relevance to warrant being the subject of my PhD.
In the growth hormone workshop I was impressed
with the number of patients whose lives had been
converted by growth hormone replacement therapy. I
was struck by the amount of anger voiced by the many
patients whose lives had returned to being suboptimal
when their clinical trial was discontinued. One young
Irish man, convinced that I was a fellow growth
hormone deficiency sufferer, asked me if I was thinking
about taking growth hormone replacement. He told
me that he was now going to the gym five times a week
(he certainly looked fitter than me) and was paying
£5000 a year of his own money to continue his
treatment.
Having attended this conference, I am now finding
the pituitary clinics to be more rewarding and
stimulating. As well as concerning myself with the
endocrine status of the patients, I am trying to
remember to ask about their ongoing symptoms and
concerns.
It is essential for us to keep up to date with the
science behind our specialties, but it is equally
important to understand our patients’ ideas, concerns,
and expectations. Moreover, good scientific ideas come
from basic clinical observation. Personally, I learnt as
much about pituitary disease at this patient led
conference as I have at any scientific meeting.
Miles Levy specialist registrar in endocrinology, National
Hospital for Neurology and Neurosurgery, London
To find out more about the Pituitary Foundation visit
its website, www.pituitary.org.uk
We welcome articles of up to 600 words on topics such
as A memorable patient, A paper that changed my practice,
My most unfortunate mistake, or any other piece
conveying instruction, pathos, or humour. If possible
the article should be supplied on a disk. Permission is
needed from the patient or a relative if an identifiable
patient is referred to. We also welcome contributions
for “Endpieces,” consisting of quotations of up to 80
words (but most are considerably shorter) from any
source, ancient or modern, which have appealed to the
reader.
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